ClinicalTrials.gg
RecruitingNCT07727083EBV-T/NK CohorUpdated Aug 13, 2026

Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases

An observational study in Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia and Systemic Chronic Active Epstein-Barr Virus Disease, sponsored by Rong Tao. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Rong Tao · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China — 22 open to participants now, 25 under way, 2 of them phase 3. Lymphoma, Extranodal NK-T-Cell · China.

Started
2026
with 7 others
Observational
7 of 73
5 open now
Primary completion
2035-12
later than 24 of 24 live
Registered
71st of 73
by date
Lead sponsor
4 of 73
Rong Tao

Among the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, this one is one of 8 that started in 2026, is one of 7 observational ones, reaches primary completion later than 24 of the 24 other live ones, and was the 71st registered.

Lymphoma, Extranodal NK-T-Cell

270 studies on the registry are indexed under Lymphoma, Extranodal NK-T-Cell; 36 are open to participants now.

Browse Lymphoma, Extranodal NK-T-Cell studies →

Open to participants now

22 of the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Lymphoma, Extranodal NK-T-Cell studies recruiting now, 11 (55%) set no upper age limit and 8 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases. The study consists of a retrospective clinical cohort of 500 consecutively diagnosed patients with extranodal NK/T-cell lymphoma and a prospective clinical-biological cohort of 1,000 newly diagnosed patients with extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, or Epstein-Barr virus-positive nodal T/NK-cell lymphoma.

The study will characterize clinical features, treatment pathways, response, relapse or progression patterns, and long-term survival. The prospective cohort will additionally undergo standardized collection of peripheral blood and optional tumor tissue specimens at predefined clinical time points. Clinical, molecular, viral, and immune biomarkers will be evaluated for their associations with treatment response, treatment failure, disease progression, and survival. No treatment is assigned by the study.

Read the detailed description

Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases comprise a heterogeneous spectrum of disorders that share viral and immunobiological features but differ substantially in clinical presentation, disease course, treatment, and prognosis. Extranodal NK/T-cell lymphoma is the principal disease entity in this study and will constitute the core population for clinical outcome analyses and development of integrated clinical-molecular prognostic models.

The study includes two cohorts. Cohort A is a retrospective cohort of approximately 500 consecutive hospitalized patients with newly diagnosed extranodal NK/T-cell lymphoma diagnosed between January 1, 2020 and December 31, 2025. Patients are identified through pathology records, followed by clinical verification and confirmation of survival follow-up. Cohort A includes clinical data only.

Cohort B is a prospective clinical-biological cohort of approximately 1,000 consecutive newly diagnosed patients enrolled between June 1, 2026 and December 31, 2030. Eligible disease entities include extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, and Epstein-Barr virus-positive nodal T/NK-cell lymphoma. Extranodal NK/T-cell lymphoma will account for at least 80% of Cohort B.

Treatment is determined by treating physicians according to routine clinical practice and is not assigned by the study. Clinical information includes baseline disease characteristics, pathology, laboratory and imaging findings, treatment exposures, response assessments, adverse events, relapse or progression, subsequent treatment, and survival.

Prospective participants provide a 10-mL peripheral blood sample before treatment and are scheduled for additional sample collection after two treatment cycles, at the end of treatment or first formal end-of-treatment assessment, and at relapse or refractory disease confirmation. Plasma and peripheral blood mononuclear cells are stored in two aliquots at participating-center biobanks. Tumor tissue is optional. Molecular, viral, immune, and tumor microenvironment analyses will be performed within the scope approved by the protocol and informed consent.

The main clinical outcomes are overall survival and progression-free survival. Secondary outcomes include objective response rate, complete response rate, primary refractory disease, early progression, relapse or progression patterns, post-relapse survival, grade 3 or higher adverse events, serious infections, treatment-related mortality, and longitudinal changes in plasma Epstein-Barr virus DNA, circulating tumor DNA, and immune biomarkers.

03

Conditions studied

  • Extranodal NK/T-cell Lymphoma
  • Aggressive NK-Cell Leukemia
  • Systemic Chronic Active Epstein-Barr Virus Disease
  • Epstein-Barr Virus-Positive Nodal T/NK-Cell Lymphoma
  • Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Disease

Keywords

  • Epstein-Barr virus
  • T/NK-cell lymphoproliferative disease
  • extranodal NK/T-cell lymphoma
  • aggressive NK-cell leukemia
  • chronic active Epstein-Barr virus disease
  • EBV-positive nodal T/NK-cell lymphoma
  • circulating tumor DNA
  • plasma EBV-DNA
  • immune profiling
  • molecular biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older with a newly diagnosed Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease meeting World Health Organization diagnostic criteria. The retrospective cohort includes consecutive hospitalized patients with extranodal NK/T-cell lymphoma diagnosed from 2017 through 2025. The prospective cohort includes consecutive newly diagnosed patients with extranodal NK/T-cell lymphoma or one of the prespecified rare Epstein-Barr virus-positive T/NK-cell disease entities from 2026 through 2030.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Newly diagnosed Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease meeting World Health Organization diagnostic criteria.
  • For the retrospective cohort: diagnosis of extranodal NK/T-cell lymphoma between January 1, 2017 and December 31, 2025 at a participating center.
  • For the prospective cohort: diagnosis between June 1, 2026 and December 31, 2030 of one of the following:
  • Extranodal NK/T-cell lymphoma;
  • Aggressive NK-cell leukemia;
  • Systemic chronic active Epstein-Barr virus disease of T/NK-cell type; or Epstein-Barr virus-positive nodal T/NK-cell lymphoma.
  • Availability of essential diagnostic, staging, and treatment information.
  • For the prospective cohort: written and successful collection of the protocol-required baseline peripheral blood specimen.

Exclusion criteria

Exclusion Criteria:

  • For the retrospective cohort: no usable survival follow-up information, inability to confirm survival status, or inability to calculate the principal survival outcomes.
  • For the prospective cohort: unwillingness or inability to participate in protocol-defined longitudinal clinical follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective NKTCL Cohort

    Approximately 500 consecutive hospitalized patients with newly diagnosed extranodal NK/T-cell lymphoma diagnosed between January 1, 2017 and December 31, 2025. Clinical, treatment, response, relapse, safety, and survival information is collected from medical records and follow-up records. No biospecimen collection is mandated.

  • Prospective EBV-Positive T/NK Disease Cohort

    Approximately 1,000 consecutive newly diagnosed patients enrolled between June 1, 2026 and December 31, 2030. Eligible diseases include extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, and Epstein-Barr virus-positive nodal T/NK-cell lymphoma. Clinical information, longitudinal outcomes, and protocol-defined biospecimens are collected. Extranodal NK/T-cell lymphoma will represent at least 80% of this cohort.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as the time from the date of initial diagnosis to death from any cause. Participants who are alive will be censored at the date on which their survival status was last confirmed.

    Time frame: From initial diagnosis to death or last confirmed follow-up, assessed for up to 10 years.

  2. Progression-Free Survival

    Progression-free survival is defined as the time from the date of initial diagnosis to the first documented disease progression, disease relapse, or death from any cause, whichever occurs first. Participants without an event will be censored at the date of the last assessment confirming absence of progression.

    Time frame: From initial diagnosis to progression, relapse, death, or last disease assessment, assessed for up to 10 years.

Secondary outcomes

  1. Objective Response Rate

    The proportion of response-evaluable participants who achieve a best response of complete response or partial response during first-line treatment. The response-evaluable population includes participants who undergo at least one formal response assessment.

    Time frame: From initiation of first-line treatment through the first-line end-of-treatment assessment, assessed for up to 24 months.

  2. Complete Response Rate

    The proportion of response-evaluable participants who achieve complete response during first-line treatment.

    Time frame: From initiation of first-line treatment through the first-line end-of-treatment assessment, assessed for up to 24 months.

  3. Grade 3 or Higher Adverse Events

    The proportion of participants experiencing grade 3 or higher adverse events during systemic anticancer treatment, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: During each treatment line, from treatment initiation through treatment completion, assessed for up to 24 months per treatment line.

  4. Treatment-Related Mortality

    The proportion of participants whose death is assessed as related to anticancer treatment.

    Time frame: From initiation of first anticancer treatment to 30 days after the last administered treatment, assessed for up to 10 years across treatment lines.

Other outcomes

  1. Plasma Epstein-Barr Virus (EBV) DNA Level

    Plasma Epstein-Barr virus (EBV) DNA level (Copies/mL) will be quantitatively measured by real-time polymerase chain reaction (PCR) at predefined clinical time points in the prospective cohort.

    Time frame: Baseline, after 2 treatment cycles, at end of treatment, and at relapse or refractory disease confirmation; assessed for up to 10 years.

  2. Circulating Tumor DNA Mutation Detection Status

    The presence or absence of tumor-derived somatic mutations detected in circulating tumor DNA will be evaluated by next-generation sequencing at predefined clinical time points.

    Time frame: Baseline, after 2 treatment cycles, at end of treatment, and at relapse or refractory disease confirmation; assessed for up to 10 years.

  3. Peripheral Blood Immune Cell Subset Frequencies

    Frequencies of immune cell subsets in peripheral blood, including EBV-infected cell subsets when applicable, will be evaluated by flow cytometry at predefined clinical time points.

    Time frame: Baseline, after 2 treatment cycles, at end of treatment, and at relapse or refractory disease confirmation; assessed for up to 10 years.

  4. Peripheral Blood Cytokine Concentrations

    Peripheral Blood Cytokine Concentrations

    Time frame: Baseline, after 2 treatment cycles, at end of treatment or formal end-of-treatment assessment, and at relapse or refractory disease confirmation; assessed for up to 10 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. PubMed 25113753 ↗
  • Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R. Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study. Blood Adv. 2026 Mar 3:bloodadvances.2025018720. doi: 10.1182/bloodadvances.2025018720. Online ahead of print. PubMed 41774854 ↗
  • Zhu Y, Tian S, Xu L, Ma Y, Zhang W, Wang L, Jin L, Liu C, Zhu C, Li Z, Hao S, Zhong H, Ding H, Tao R. GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study. Br J Haematol. 2022 Feb;196(4):939-946. doi: 10.1111/bjh.17960. Epub 2021 Nov 21. PubMed 34806163 ↗
  • Liu C, Ding H, Zhu Q, Liu P, Zhu Y, Wang L, Ma Y, Zhang W, Tian S, Zhang X, Jin L, Liu L, Li Z, Hao S, Tao R. Induction with MEDA regimen and consolidation with Auto-HSCT for stage IV NKTCL patients: A prospective multicenter study. Int J Cancer. 2022 Sep 1;151(5):752-763. doi: 10.1002/ijc.34055. Epub 2022 Jun 9. PubMed 35489026 ↗
  • Oishi N, Ahmed R, Feldman AL. Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders. Curr Hematol Malig Rep. 2023 Dec;18(6):252-263. doi: 10.1007/s11899-023-00712-9. Epub 2023 Oct 23. PubMed 37870698 ↗
  • Luniewski A, Chaudhary S, Goldfarb A, Obiorah IE. EBV-Driven NK/T-Cell Lymphoproliferative Disorders: Clinical Diversity and Molecular Insights. Lymphatics. 2026 Mar;4(1):7. doi: 10.3390/lymphatics4010007. Epub 2026 Jan 26. PubMed 41657941 ↗

Individual participant data

Plan to share: Undecided — Individual participant data will not be made publicly available because the current informed consent and multicenter data governance framework do not authorize unrestricted public sharing. Deidentified data may be considered for qualified scientific requests subject to approval by the study steering committee, participating institutions, and applicable ethics committees.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2035, 112 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2026
First posted
Jul 27, 2026
StartActual
Aug 11, 2026
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2035
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07727083
Lead sponsor
Rong Tao
Responsible party
Rong Tao (Department head, professor, Fudan University) — Sponsor-investigator
First posted
Jul 27, 2026
Start date
Aug 11, 2026
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Aug 13, 2026

Study contacts

Rong Tao, MD
Contact
hkutao@hotmail.com
008621-64175590 ext. 660103
Chuanxu Liu, MD
Contact
liuchaunxu@shca.or.cn
008621-64175590 ext. 660103

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion